The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Margalit, A.
Right arrow Articles by Gross, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Margalit, A.
Right arrow Articles by Gross, G.
The Journal of Immunology, 2006, 176: 217-224.
Copyright © 2006 by The American Association of Immunologists

Induction of Antitumor Immunity by CTL Epitopes Genetically Linked to Membrane-Anchored {beta}2-Microglobulin1

Alon Margalit2,*,{dagger}, Helena M. Sheikhet2,{ddagger}, Yaron Carmi3,*, Dikla Berko4,*, Esther Tzehoval{ddagger}, Lea Eisenbach{ddagger} and Gideon Gross5,*,{dagger}

* Laboratory of Immunology, MIGAL-Galilee Technology Center, Kiryat Shmona, Israel; {dagger} Department of Biotechnology, Tel-Hai Academic College, Upper Galilee, Israel; and {ddagger} Department of Immunology, Weizmann Institute of Science, Rehovot, Israel

Level and persistence of antigenic peptides presented by APCs on MHC class I (MHC-I) molecules influence the magnitude and quality of the ensuing CTL response. We recently demonstrated the unique immunological properties conferred on APCs by expressing {beta}2-microglobulin ({beta}2m) as an integral membrane protein. In this study, we explored membrane-anchored {beta}2m as a platform for cancer vaccines using as a model MO5, an OVA-expressing mouse B16 melanoma. We expressed in mouse RMA-S cells two H-2Kb binding peptides from MO5, OVA257–264, and TRP-2181–188, each genetically fused with the N terminus of membranal {beta}2m via a short linker. Specific Ab staining and T cell hybridoma activation confirmed that OVA257–264 was properly situated in the MHC-I binding groove. In vivo, transfectants expressing both peptides elicited stronger CTLs and conferred better protection against MO5 than peptide-saturated RMA-S cells. Cells expressing OVA257–264/{beta}2m were significantly superior to OVA257–264-charged cells in their ability to inhibit the growth of pre-established MO5 tumors. Our results highlight the immunotherapeutic potential of membranal {beta}2m as a universal scaffold for optimizing Ag presentation by MHC-I molecules.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.